34,871 Shares in Repligen Corporation $RGEN Bought by Roubaix Capital LLC

Key Points

• Roubaix Capital LLC has acquired a new stake worth approximately $4.44 million in Repligen Corporation, purchasing about 34,871 shares, making it the firm's 18th largest holding.
• Analysts have mixed views on Repligen, with target price adjustments ranging from $130.00 to $204.00, while maintaining an average rating of "Moderate Buy" with a target price of $169.45.
• Repligen recently reported earnings of $0.37 per share, missing consensus estimates, despite achieving 14.8% revenue growth year-over-year, with reported revenues of $182.37 million.

Roubaix Capital LLC acquired a new stake in Repligen Corporation (NASDAQ:RGEN - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 34,871 shares of the biotechnology company's stock, valued at approximately $4,437,000. Repligen accounts for 2.3% of Roubaix Capital LLC's investment portfolio, making the stock its 18th biggest holding. Roubaix Capital LLC owned about 0.06% of Repligen as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in RGEN. Sterling Capital Management LLC lifted its stake in shares of Repligen by 51.8% in the 4th quarter. Sterling Capital Management LLC now owns 2,982 shares of the biotechnology company's stock valued at $429,000 after purchasing an additional 1,017 shares during the period. Farringdon Capital Ltd. acquired a new position in Repligen during the 4th quarter worth approximately $224,000. Canada Pension Plan Investment Board acquired a new position in Repligen during the 4th quarter worth approximately $792,000. CANADA LIFE ASSURANCE Co raised its stake in Repligen by 17.7% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 41,175 shares of the biotechnology company's stock worth $5,924,000 after buying an additional 6,200 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in Repligen by 28.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 580,485 shares of the biotechnology company's stock worth $83,556,000 after buying an additional 126,913 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

RGEN has been the topic of a number of research reports. Wells Fargo & Company dropped their price target on Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a research note on Wednesday, July 30th. Wall Street Zen downgraded Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Evercore ISI dropped their price target on Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 8th. Royal Bank Of Canada upped their price target on Repligen from $193.00 to $204.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 30th. Finally, JPMorgan Chase & Co. dropped their price target on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, Repligen currently has an average rating of "Moderate Buy" and a consensus target price of $169.45.

Insiders Place Their Bets

In other news, Director Martin D. Madaus acquired 1,800 shares of Repligen stock in a transaction on Friday, August 8th. The stock was acquired at an average cost of $112.13 per share, with a total value of $201,834.00. Following the completion of the acquisition, the director owned 1,800 shares in the company, valued at approximately $201,834. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.20% of the company's stock.

Repligen Stock Performance

Shares of RGEN stock traded down $1.94 during trading on Wednesday, hitting $121.56. The company's stock had a trading volume of 735,985 shares, compared to its average volume of 780,342. The company has a market cap of $6.84 billion, a PE ratio of -486.22, a P/E/G ratio of 2.28 and a beta of 1.05. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. The business has a fifty day moving average of $122.16 and a 200-day moving average of $132.13. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). The business had revenue of $182.37 million during the quarter, compared to the consensus estimate of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The business's revenue was up 14.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, research analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.